The largest database of trusted experimental protocols

Parteck m200

Manufactured by Merck Group
Sourced in Germany

Parteck M200 is a laboratory equipment product manufactured by the Merck Group. It is designed for general laboratory use. The core function of Parteck M200 is to provide a reliable and versatile tool for various laboratory applications. No further details or interpretations are provided.

Automatically generated - may contain errors

9 protocols using parteck m200

1

Formulation and Coating of Compound A Tablets

Check if the same lab product or an alternative is used in the 5 most similar protocols

Example 2

60.90 g of mannitol (Parteck M200, Merck) and 3.60 g croscarmellose sodium were added to 53.70 g of maleate of Compound A and the mixture was mixed for 10 minutes. 1.80 g of magnesium stearate was added to the mixed powder and the mixture was mixed for 30 minutes. The mixed powder was tableted at a tableting pressure of about 10 kN using a pestle having a double rounded surface with a tablet diameter of 8.5 mm to obtain round uncoated tablets each weighing 250 mg. The uncoated tablets were coated with 8 mg of a coating agent (Opadry 03F44057, 00F440000 (hypromellose 2910: 71.5%, Macrogol 6000: 14.166%, talc: 7.167%, titanium oxide: 7.067%, iron sesquioxide: 0.1%), Colorcon Japan LLC) per tablet, and then a small amount of carnauba wax was added thereto to give film-coated tablets.

+ Open protocol
+ Expand
2

Mannitol Powder Particle Size Effects

Check if the same lab product or an alternative is used in the 5 most similar protocols
β mannitol (Pearlitol® 160C) was acquired from Roquette Frères (Lestrem, France), and δ mannitol (Parteck® Delta M) and spray granulated β mannitol (Parteck® M200) were supplied by Merck KGaA (Darmstadt, Germany). Magnesium stearate was purchased from Peter Greven (Bad Münstereifel, Germany). All powders were sieved through a 1 mm sieve using a Turbosieve BTS 100 (L.B. Bohle, Ennigerloh, Germany) with a speed of 355 rpm. The influence of initial powder particle size on granules and tablet properties was investigated by comparison of two different particle size distributions of β mannitol powder: the initial 1 mm turbosieved powder and a fraction smaller than 180 µm of the β mannitol (180 β mannitol) powder. Therefore, after sieving with the turbosieve, a fraction of Pearlitol® 160C powder was again manually sieved through a sieve with a mesh size of 180 µm (Retsch GmbH, Haan, Germany) before further processing.
+ Open protocol
+ Expand
3

Eutectic Insulin Melt-in-Mouth Tablets

Check if the same lab product or an alternative is used in the 5 most similar protocols

Example 8

Components of eutectic mixture (Menthol, Vitamin E succinate and lecithin) were combined with Mannitol (Parteck® M200, Merck), colloidal silicon dioxide, PEG stearate and polyvinylpyrrolidone. The crystalline insulin was added, followed by sweetener and lubricant (PEG-3350); further mixed, screened and then round tablets (approximate weight 160 mg) were compressed to form tablets with hardness of 4-5 kP and that dissolved in the mouth in 4-9 minutes.

Example 9

These Examples were prepared in a similar manner as described in Example 8; however, Examples 9-14 have higher content of eutectic components and additionally contain different counter-ions and anionic surfactants (ammonium glycyrrhizinate, sodium deoxycholate, sodium dioctylsulfosuccinate) and bioadhesive polymers. In some formulations Sorbitol was used instead of Xylitol. The formulation of Example 13 additionally contained bioadhesive polymer (Chitosan).

+ Open protocol
+ Expand
4

Rapid Dissolving Insulin Tablets

Check if the same lab product or an alternative is used in the 5 most similar protocols

Example 6

Mannitol (Parteck® M200, Merck) and colloidal silicon dioxide were mixed with lecithin, PEG stearate and polyvinylpyrrolidone. After the addition of crystalline insulin and a sweetener, the mixture was screened and then round 8 mm tablets (approximate weight 213 mg) were compressed to form tablets of hardness 7-10 kP hardness that dissolved in the mouth in 15-20 minutes.

+ Open protocol
+ Expand
5

Formulation and Coating of Compound A Tablets

Check if the same lab product or an alternative is used in the 5 most similar protocols

Example 2

60.90 g of mannitol (Parteck M200, Merck) and 3.60 g croscarmellose sodium were added to 53.70 g of maleate of Compound A and the mixture was mixed for 10 minutes. 1.80 g of magnesium stearate was added to the mixed powder and the mixture was mixed for 30 minutes. The mixed powder was tableted at a tableting pressure of about 10 kN using a pestle having a double rounded surface with a tablet diameter of 8.5 mm to obtain round uncoated tablets each weighing 250 mg. The uncoated tablets were coated with 8 mg of a coating agent (Opadry 03F44057, 00F440000 (hypromellose 2910: 71.5%, Macrogol 6000: 14.166%, talc: 7.167%, titanium oxide: 7.067%, iron sesquioxide: 0.1%), Colorcon Japan LLC) per tablet, and then a small amount of carnauba wax was added thereto to give film-coated tablets.

+ Open protocol
+ Expand
6

Mannitol-based Tablet Formulation for Compound A

Check if the same lab product or an alternative is used in the 5 most similar protocols

Example 2

60.90 g of mannitol (Parteck M200, Merck) and 3.60 g croscarmellose sodium were added to 53.70 g of maleate of Compound A and the mixture was mixed for 10 minutes. L80 g of magnesium stearate was added to the mixed powder and the mixture was mixed for 30 minutes. The mixed powder was tableted at a tableting pressure of about 10 kN using a pestle having a double rounded surface with a tablet diameter of 8.5 mm to obtain round uncoated tablets each weighing 250 mg. The uncoated tablets were coated with 8 mg of a coating agent (Opadry 03F44057, 00F440000 (hypromellose 2910: 71.5%, Macrogol 6000: 14.166%, talc: 7.167%, titanium oxide: 7.067%©, iron sesquioxide: 0.1%), Colorcon Japan LLC) per tablet, and then a small amount of carnauba wax was added thereto to give film-coated tablets.

+ Open protocol
+ Expand
7

Carbopol-based Oral Insulin Formulation

Check if the same lab product or an alternative is used in the 5 most similar protocols

Example 5

Formulation with Carbopol 974P NF (Lubrizol Corp.) was prepared similarly, but without addition of an amino acid. Mannitol (Parteck® M200, Merck), microcrystalline cellulose (Vivapur® 102), Carbopol 974P NF (Lubrizol Corp.), lecithin, polyvinylpyrrolidone and colloidal silicon dioxide were combined. After the addition of crystalline insulin and a sweetener, the blend was mixed, screened and then round 8 mm tablets (approximate weight 257 mg) were compressed to form tablets with 5-9 kP hardness. The formed tablets dissolved in the mouth in 20-35 minutes.

+ Open protocol
+ Expand
8

Directly Compressible Ketoprofen Tablets

Check if the same lab product or an alternative is used in the 5 most similar protocols
Ketoprofen was supplied by S&D Chemical, UK. As diluents, directly compressible lactose (lactose DC) (Supertab 14 SD) from DMV-Fonterra Excipients GmbH&Co, Germany; directly compressible mannitol (mannitol DC) (Parteck M200) from Merck, Germany; directly compressible isomalt (isomalt DC) (GalenIQ 721) from BENEO-Palatinit GmbH, Germany were used. As matrix-forming excipient Kollidon® SR, from BASF-Germany, was used. Hydrophilic fumed silica (Aerosil® 200), manufactured by Degussa AG -Germany was used as flow improver of powder blends and also as anticaking agent. Lubricant (magnesium stearate) was supplied by Merck, Germany.
+ Open protocol
+ Expand
9

Formulation and Characterization of Tablet Excipients

Check if the same lab product or an alternative is used in the 5 most similar protocols
Microcrystalline cellulose (Avicel PH101, Avicel PH105, Avicel PH301, FMC Biopolymer, Philadelphia, USA), α-lactose monohydrate (Pharmatose 200M, Pharmatose 350M, DFE Pharma, Goch, Germany and GranuLac 200, Meggle Group, Wasserburg, Germany) and mannitol (Parteck M200, Parteck Delta M, Merck, Darmstadt, Germany) were used as fillers. Hydroxypropyl methylcellulose (Pharmacoat 603, Shin Etsu, Tokyo, Japan) and polyvinylpyrrolidone (Kollidon K30, BASF, Ludwigshafen, Germany) were used as binders in this study. Croscarmellose sodium (Disolcel GF, Mingtai Chemical Co, Taoyuan Hsien, Taiwan), magnesium stearate (Mallinckrodt, St. Louis, USA) and colloidal silicon dioxide (Aerosil 200, Evonik, Rheinfelden, Germany) were used to prepare the final blend for tablet compression.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!